EXEL (Exelixis Inc) Earnings per share for the last four quarters

Public company logo of Exelixis Inc (EXEL)

Under the leadership of Michael Morrissey, Exelixis, Inc. (EXEL) has evolved into an efficient financial machine, successfully monetizing its oncology developments. Historical EPS YoY TTM dynamics demonstrate current earnings, with the metric recorded at 40.20. The company is actively investing in the discovery of new molecules for targeted therapy, seeking to mitigate the risks of key patent expirations by expanding its R&D portfolio.

EXEL exelixis.com Earnings per share for the last twelve months (02/11/2024 - 11/16/2026)

Exelixis Inc - analytical breakdowns and key metrics (EXEL)

- current price and projected stock value:
- business market valuation indicators:
Fundamental valuation:Exelixis (EXEL)
Signature product of Exelixis

For Exelixis, Inc. (EXEL), earnings per share dynamics reflect the monetization efficiency of its patent-protected oncology portfolio. This metric compares total net income over the last 12 months with the same period last year, measuring the rate of capital expansion. By analyzing the annual growth trend of TTM net income per share, an investor can discern the actual speed of business scaling. The monopoly status of the drugs ensures the stability of this indicator.

Competitor analysis for Exelixis, Inc.

Earnings per share for the trailing year GMAB (Genmab US)|NUVL (Nuvalent) - Net earnings per share for the last 12 months|KYMR: Earnings per share for the last four quarters|IDYA (IDEAYA Corp) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) enliventherapeutics.com|Earnings per share for the last twelve months ORIC Pharmaceuticals, Inc. (ORIC)|RLAY (Relay Therapeutics, Inc.) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) NRIX (Nurix Therapeutics Inc)|Net earnings per share for the trailing year Tyra Bio|Verastem Oncology - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Monte Rosa Therapeutics, Inc.|CGEM (Cullinan Therapeutics) - Net earnings per share for the last 12 months|IMRX: Earnings per share for the last four quarters|CCCC (c4therapeutics.com) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Black Diamond Therapeutics Inc. BDTX|Net earnings per share (EPS TTM) RPTX|PMV Pharmaceuticals, Inc. - Earnings per share for the last 12 months|Karyopharm Therapeutics - Net earnings per share for the last 12 months|Earnings per share for the trailing year PPCB|BGMS: Net earnings per share for the last 12 months|aadibio.com - Earnings per share for the last four quarters|ALRN: Net earnings per share (EPS TTM)|Blueprint Medicines Corp. - Earnings per share for the trailing year|GLYC (GlycoMimetics Inc.) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months SpringWorks Therapeutics Inc. SWTX